Site–Specific (Targeted) Drug Delivery in Cancer Therapy

Abstract

The current status of efforts to target cytotoxic agents to tumor cells using antitumor antibodies and particulate drug carriers such as liposomes and microspheres is reviewed. Emphasis is given to the role of anatomic and physiologic factors in determining the disposition, fate, and therapeutic efficacy of targeted drug delivery systems and to the importance of tumor cell heterogeneity as a major obstacle to effective cancer therapy.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    DeVita, V.T. Jr., Hellman, S. and Rosenberg, S.A. (eds.) 1982. Cancer: Principles and Practice of Oncology. Lippincott, Philadelphia.

  2. 2

    Poste, G. and Fidler, I.J. 1980. The pathogenesis of cancer metastasis. Nature 283: 139–146.

  3. 3

    Poste, G. 1982. Experimental systems for analysis of the malignant phenotype. Cancer Met. Rev. 1: 141–199.

  4. 4

    Ehrlich, P. 1906. Collected Studies on Immunity. Reprinted. 2: 442–447. Wiley, New York.

  5. 5

    Sikora, K. and Smedley, M. 1982. Clinical potential of monoclonal antibodies. Cancer Surveys 1: 521–542.

  6. 6

    Trowbridge, I.S. and Domingo, D.L. 1982. Prospects for the clinical use of cytotoxic monoclonal antibody conjugates in the treatment of cancer. Cancer Surveys 1: 543–556.

  7. 7

    Foon, K.A., Bernhard, M.I. and Oldham, R.K. 1982. Monoclonal antibody therapy: assessment by animal tumor models. J. Biol. Resp. Modifiers 1: 277–304.

  8. 8

    Levy, R. and Miller, R.A. 1983. Tumor therapy with monoclonal antibodies. Fed. Proc. 42: 2650–2656.

  9. 9

    Arnon, R. and Sela, M. 1982. Targeted chemotherapy: drugs conjugated to anti-tumor antibodies. Cancer Surveys 1: 429–449.

  10. 10

    Olsner, S. and Pihl, A. 1982. Cytotoxic proteins with intracellular site of action: mechanism of action and anti-cancer properties. Cancer Surveys 1: 467–487.

  11. 11

    Gregoriadis, G., Senior, J., and Trouet, A. (eds.) 1982. Targeting of Drugs. Plenum, New York.

  12. 12

    Nicolau, C. and Poste, G. (eds.) 1983. Liposomes in vivo. Biol. Cell. (Special Issue) 47: 1–133.

  13. 13

    Poste, G., Bucana, C., Raz, A., Bugelski, P., Kirsh, R. and Fidler, I.J. 1982. Analysis of the fate of systemically administered liposomes arid implications for their use in drug delivery. Cancer Res. 42: 1412–1422.

  14. 14

    Bruck, S.D. (ed.) 1982. Controlled Drug Delivery. CRC, Boca Raton.

  15. 15

    Tomlinson, G. 1983. Unpublished data.

  16. 16

    Widder, K.J., Senyei, A.E. and Sears, B. 1982. Experimental methods in cancer therapeutics. J. Pharm. Sci. 71: 379–387.

  17. 17

    Poste, G. and Nicolson, G.L. 1983. Experimental systems for analysis of the surface properties of metastatic tumor cells, p. 341–364. In: Biomembranes. Volume II. A. Nowotny (ed.), Plenum, New York.

  18. 18

    Baldwin, R.W. and Pimm, M.V. 1983. Antitumor monoclonal antibodies for radioimmunodetection of tumors and drug targeting. Cancer Met. Rev. 2: 89–106.

  19. 19

    Peterson, H.I. (ed.) 1979. Tumor Blood Circulation: Angiogenesis, Vascular Morphology and Blood Flow of Experimental and Human Tumors. CRC, Boca Raton.

  20. 20

    Folkman, J. and Haudenschild, C. 1981. Induction of capillary growth in vitro, p. 119–136. In: J.T. Dingle and J.L. Gordon (eds.) Cellular-Interactions. Elsevier, Amsterdam.

  21. 21

    Poste, G. 1983. Liposome targeting in vivo: Problems and opportunities. Biol. Cell. 47: 19–39.

  22. 22

    Poste, G. 1983. Liposomes as a drug delivery system in cancer therapy. In: P. Sunkara (ed.), Novel Approaches to Cancer Chemotherapy. Academic, New York.

  23. 23

    Parker, R.J., Sieber, S.M. and Weinstein, J.N. 1981. Effect of liposome encapsulation of a fluorescent dye on its uptake by the lymphatics of the rat. Pharmacology 23: 128–136.

  24. 24

    Mayhew, E., Rustum, Y.M. and Szoka, F. 1982. Therapeutic efficacy of cytosine arabinoside trapped in liposomes, p. 249–260. In: Targeting of Drugs. G. Gregoriadis, J. Senior, and A. Trouet (eds.), Plenum, New York.

  25. 25

    Hunt, C.A. 1982. Liposonres disposition in vivo. V. Liposome stability in plasma and implications for drug carrier function. Biochim. Biophys. Acta 719: 450–463.

  26. 26

    Profitt, R.T., Williams, L.E., Presant, C.A., Tin, G.W., Uliana, J.A., Gamble, R.C. and Baldeschwieler, J.D. 1983. Liposomal blockade of the reticuloendothelial system: Improved tumor imaging with small unilamellar vesicles. Science 220: 502–505.

  27. 27

    Dobson, E.L. and Jones, H.B. 1982. The behavior of intravenously injected particulate material. Its rate of disappearance from the blood stream as a measure of liver blood flow. Acta Med. Scand. 273 1–71.

  28. 28

    Kato, T. 1982. Encapsulated drugs in targeted cancer therapy, p. 189–240. In: Controlled Drug Delivery, Vol. II. CRC, Boca Raton.

  29. 29

    Greaves, M.F. 1982. “Target” structures and “target” cells for cancer therapy with monoclonal antibodies: finding the candidates. Cancer Surveys 1: 451–466.

  30. 30

    Olsson, L. 1983. Phenotypic diversity in leukemia cell populations. Cancer Met. Rev. 2: 153–164.

  31. 31

    Webb, K.S., Ware, J.L., Parks, S.F., Briner, W.H., and Paulson, D.F. 1983. Monoclonal antibodies of different epitopes on a prostate tumor-associated antigen: Implications for immunotherapy. Cancer Immunol. Immunother. 14: 155–166.

  32. 32

    Machy, P., Barbet, J. and Leserman, L.D. 1982. Differential endocytosis of T and B lymphocyte surface molecules evaluated with anti body-bearing fluorescent liposomes containing methotrexate. Proc. Natl. Acad. Sci. USA 79: 4148–4152.

  33. 33

    Bragman, K.S., Heath, T.D. and Papahadjopoulos, D. 1983. Simultaneous interaction of monoclonal antibody-targeted liposomes with two receptors on K562 cells. Biochim. Biophys. Acta 730: 187–195.

  34. 34

    Marx, J.L. 1983. Suppressing autoimmunity in mice. Science 221: 843–845.

  35. 35

    Lynch, W.E., Sartiano, G.P. and Ghaffar, A. 1980. Erythrocytes as carriers of chemotherapeutic agents for targeting to the reticuloendothelial system. Am. J. Hematol. 9: 249–259.

  36. 36

    Anghileri, L.J. (ed.) 1982. General Processes of Radiotracer Localization, Vols. I and II. CRC, Boca Raton.

  37. 37

    Poste, G. and Fidler, I.J. 1982. Therapeutic amplification of macrophage-mediated destruction of tumor cells: an approach to cancer therapy that addresses the problem of tumor cell heterogeneity, p. 225–238. In: Design of Models for Testing Cancer Therapeutic Agents. I.J. Fidler and R.J. White (eds.), Van Nostrand, New York.

  38. 38

    Fidler, I.J. and Poste, G. 1982. Macrophage-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic disease. Springer Semin. Immunopathol. 5: 161–174.

  39. 39

    Lopez-Berestein, G., Mehta, R., Hopfer, R.L., Mills, K., Kasi, L., Mehta, K., Fainstein, V., Luna, M., Hersh, E.M. and Juliano, R. 1983. Treatment of prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J. Infec. Dis. 5: 939–945.

  40. 40

    Graybill, J.R., Craven, P.C., Taylor, R.L., Williams, D.M. and Magee, W.E. 1982. Treatment of murine cryptococcosis with liposome associated amphotericin B. J. Infect. Dis. 145: 748–751.

  41. 41

    Khato, J., Priester, E.R. and Sieber, S.M. 1982. Enhanced lymph node uptake of melphalan following liposomal entrapment and effects on lymph node metastasis in rats. Cancer Treatment Rep. 66: 517–527.

  42. 42

    Hashida, M., Muranishi, S., Sezaki, S., Tanigawa, N., Satomura, K. and Hikasa, Y. 1979. Increased lymphatic delivery of bleomycin by microsphere in oil emulsion and its effect on lymph node metastasis. Int. J. Pharm. 2: 245–256.

  43. 43

    Weinstein, J.N., Parker, R.J., Keenan, A.M., Dower, S.K., Morse, H.C.III and Sieber, S.M. 1982. Monoclonal antibodies in the lymphatics: toward the diagnosis and therapy of tumor metastases. Science 218: 1334–1337.

  44. 44

    Mason, D.W., Thorpe, P.E. and Ross, W.C.J. 1982. Elimination of leukaemic cells from rodent bone marrow in vitro with antibody-ricin conjugates: implications for autologous marrow transplantation in man. Cancer Surveys 1: 389–416.

  45. 45

    Muirhead, M., Martin, P.J., Torok-Storb, B., Uhr, J.W. and Vifetta, S. 1983. Use of an antibody-ricin A-chain conjugate to delete neoplastic B cells from human bone marrow. Blood 62: 327–332.

  46. 46

    Federal Register 1983. Food and Drug Administration. Proposed new drug, antibiotic and biologic drug product regulations. 48: 26720–26749.

  47. 47

    Office of Biologics, Food and Drug Administration. 1983. Points to consider in the manufacture of in vitro monoclonal antibody products subject to licensure.

  48. 48

    Haber, E. 1983. Antibodies as models for rational drug design. Biochem. Pharmacol. 32: 1967–1977.

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Poste, G., Kirsh, R. Site–Specific (Targeted) Drug Delivery in Cancer Therapy. Nat Biotechnol 1, 869–878 (1983). https://doi.org/10.1038/nbt1283-869

Download citation

Further reading